A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2002
12/05/2002	US20020182219 Cancer immunotherapy
12/05/2002	US20020182218 Therapeutic anti-melanoma compounds
12/05/2002	US20020182215 Especially the amino acid sequence Ile-Phe-Ala-Gly-Asp-Lys-Phe-Trp-Arg, preferably flanked by cysteine residues at the amino and carboxy termini.
12/05/2002	US20020182214 Tumor associated internalizing antigens and methods for targeting therapeutic agents
12/05/2002	US20020182208 Glycosylated antibody
12/05/2002	US20020182204 Combination of a taxane and a cyclin-dependent kinase
12/05/2002	US20020182188 Making by debulking a suspension of human liver tissue under conditions to remove mature cells, while retaining immature cells having markers for the expression of alpha-fetoprotein, and/or albumin
12/05/2002	US20020182181 Generated from a bacteriophage; gene expression inhibition
12/05/2002	US20020182177 Methods and compositions for promoting the maturation of monocytes
12/05/2002	US20020182176 Methods and compositions for promoting the maturation of monocytes
12/05/2002	US20020182175 Administration of a reactive oxygen species (ROS) inhibitor or scavenger (a histmine or its salt, ester, prodrug and agonist) and at least one monocyte maturation promoting agent (a cytokine)
12/05/2002	US20020182174 Methods and compositions for promoting the maturation of monocytes
12/05/2002	US20020182172 A water soluble and non-peptidic polymer backbone covalently attached to a non-heteroatom position of a triazine derivative comprising a triazine ring
12/05/2002	US20020182147 Vitronectin receptor antagonist pharmaceuticals
12/05/2002	DE10127041A1 New glycine N-(1-biphenyl-4-yl-2-substituted-ethyl)-amides, are integrin receptor inhibitors useful for treating e.g. angiogenic, cardiovascular, inflammatory and osteolytic or tumor diseases
12/05/2002	DE10126472A1 Verwendung des Nachweises der Expression von Splice-Varianten von Gen21 für die Diagnose und Therapie von Tumorerkrankungen Using the detection of the expression of splice variants of Gen21 for the diagnosis and therapy of tumor diseases
12/05/2002	CA2451838A1 Stem cell differentiation
12/05/2002	CA2449245A1 Small molecule antagonists of bcl2 family proteins
12/05/2002	CA2449199A1 Coenzyme q and eicosapentaenoic acid (epa)
12/05/2002	CA2449160A1 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002	CA2449118A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments
12/05/2002	CA2449026A1 Use of polyclonal immunoglobulins
12/05/2002	CA2449006A1 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
12/05/2002	CA2449000A1 Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis
12/05/2002	CA2448567A1 Modulators of nucleic acid ligands
12/05/2002	CA2448562A1 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
12/05/2002	CA2448528A1 Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
12/05/2002	CA2448362A1 B7 related protein-2 molecules and uses thereof
12/05/2002	CA2448348A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
12/05/2002	CA2448320A1 Ribozyme based treatment of female reproductive diseases
12/05/2002	CA2448306A1 Method for treating fibrotic diseases or other indications
12/05/2002	CA2448305A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
12/05/2002	CA2448248A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002	CA2448148A1 Carbohydrate-associated proteins
12/05/2002	CA2448146A1 Secreted proteins
12/05/2002	CA2448116A1 Molecules for disease detection and treatment
12/05/2002	CA2448109A1 Alternative splice forms of proteins as basis for multiple therapeutic modalities
12/05/2002	CA2448104A1 Wnv core protein/capsid interacting protein and uses of the same
12/05/2002	CA2448100A1 Chimeric proteins for cell targeting and apoptosis induction and methods of using the same
12/05/2002	CA2448062A1 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002	CA2448023A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
12/05/2002	CA2447879A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002	CA2447662A1 Transporters and ion channels
12/05/2002	CA2447475A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002	CA2446723A1 Antibodies that immunospecifically bind to trail receptors
12/05/2002	CA2446282A1 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives
12/05/2002	CA2445611A1 P-cadherin as a target for anti-cancer therapy
12/05/2002	CA2443713A1 Proteins associated with cell growth, differentiation, and death
12/05/2002	CA2441937A1 Chromosome-based platforms
12/05/2002	CA2411549A1 Ligands of integrin receptors
12/04/2002	EP1262555A1 Protein hollow nano particles, transporter with the use of the same and method of introducing substance into cells
12/04/2002	EP1262548A1 Polypeptide inducing apoptosis
12/04/2002	EP1262193A1 Use of human anti-CTLA-4 antibodies for treatment of cancer
12/04/2002	EP1262184A1 Compositions comprising S-tofisopam and use of these compositions for the preparation of a medicament for the treatment or prevention of convulsions or seizures
12/04/2002	EP1261744A2 Estrogen receptor beta variants and methods of detection thereof
12/04/2002	EP1261736A2 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides
12/04/2002	EP1261712A2 Proteins named fctrx and nucleic acids encoding same
12/04/2002	EP1261711A2 Compositions and methods for diagnosis and therapy of malignant mesothelioma
12/04/2002	EP1261708A2 Compositions and methods for the therapy and diagnosis of prostate cancer
12/04/2002	EP1261704A2 Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
12/04/2002	EP1261693A2 Hyperthermia and immunotherapy for leukemias, lymphomas, and solid tumors
12/04/2002	EP1261644A2 Modulation of the activity of the endothelial cell surface receptor ecrtp/dep-1 in the regulation of angiogenesis
12/04/2002	EP1261639A2 Chondromodulin-i related peptide
12/04/2002	EP1261638A2 Human fgf-23 gene and gene expression products
12/04/2002	EP1261636A2 Human protein kinases and protein kinase-like enzymes
12/04/2002	EP1261635A1 Human polynucleotides, polypeptides, and antibodies
12/04/2002	EP1261629A2 Rotavirus pseudoviral particles and use thereof for vectorizing proteins or nucleic acids
12/04/2002	EP1261627A2 Antibodies against plasma cells
12/04/2002	EP1261626A1 Bombesin analogs for treatment of cancer
12/04/2002	EP1261606A1 Substituted oxazolidinones and their use in the field of blood coagulation
12/04/2002	EP1261605A1 Benzoxazole derivatives as tnf and pde iv inhibitors
12/04/2002	EP1261604A1 Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them
12/04/2002	EP1261603A1 Flavone derivatives, preparation method and use as medicines
12/04/2002	EP1261602A1 Imidazol-2-carboxamide derivatives as raf kinase inhibitors
12/04/2002	EP1261601A1 Substituted indoles for modulating nfkb activity
12/04/2002	EP1261590A1 Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
12/04/2002	EP1261589A1 Imidazole compounds and their use as adenosine deaminase inhibitors
12/04/2002	EP1261583A1 INHIBITORS OF THE ICE/Ced-3 FAMILY OF CYSTEINE PROTEASES
12/04/2002	EP1261378A2 Biodegradable immunomodulatory formulations and methods for use thereof
12/04/2002	EP1261374A2 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
12/04/2002	EP1261372A2 Method of treating cancer with anti-neurotrophin agents
12/04/2002	EP1261371A1 Membrane estrogen receptor-directed therapy in breast cancer
12/04/2002	EP1261370A1 Therapeutic method for reducing angiogenesis
12/04/2002	EP1261369A2 Compositions and methods for tumor-targeted delivery of effector molecules
12/04/2002	EP1261367A1 Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase
12/04/2002	EP1261366A1 Adjuvant treatment by in vivo activation of dendritic cells
12/04/2002	EP1261363A2 METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS
12/04/2002	EP1261356A2 Farnesyl protein transferase inhibitor combinations with platinum compounds
12/04/2002	EP1261348A2 Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
12/04/2002	EP1261343A2 Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
12/04/2002	EP1261342A2 Farnesyl protein transferase inhibitor combinations
12/04/2002	EP1261341A2 Farnesyl protein transferase inhibitor combinations with camptothecin compounds
12/04/2002	EP1261337A2 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors
12/04/2002	EP1261332A1 Use of cyp1b1 inhibitors for treating cancer
12/04/2002	EP1261330A2 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and in lower animals
12/04/2002	EP1261329A2 Il-8 receptor antagonists
12/04/2002	EP1261328A1 Il-8 receptor antagonists
12/04/2002	EP1261326A1 D-enantiomer of dfmo and methods of use therefor for treating cancer
12/04/2002	EP1261325A2 Nitroacridine/tumor inhibitor compositions
12/04/2002	EP1261322A2 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

1 ... 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 ... 2211